DLK1 and adrenal cortex carcinoma: Our findings could thus have important implications for ACC treatment as inhibition of DLK1 could be a strategy to reduce resistance to chemotherapy in ACC, particularly the EDP (etoposide, doxorubicin, cisplatin) regimen which includes two chemotherapeutic drugs known to be ABCB1 transport substrates (etoposide and doxorubicin).